PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Polyphloretin Phosphate”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 37 records · Page 2Linked to original sources

7-oxa-13-prostynoic acid and polyphloretin phosphate as non-specific antagonists of the stimulatory effects of different agents on adenylate cyclase from various tissues.

7-oxa-13-prostynoic acid (OPA) and polyphloretin phosphate (PPP) are believed to act as specific antagonists of prostaglandin action. In order to estimate their specificity, the inhibitory effects of these drugs were tested on the activity of adenylate cyclase from several tissues which were stimulated by prostaglandins and several other compounds. In adenylate cyclase preparation from L-fibroblasts both OPA (0.15-1.5 MM) and PPP (0.01-1.0 MG/ML) antagonized not only the stimulatory effects of PGE but also the stimulatory effects of sodium fluoride and increased enzyme activity due to the previous treatment of cell cultures by cholera toxin. Both OPA and PPP produced a dose dependent depression of adenylate cyclase activity to zero values both under basal conditions and after stimulation by sodium fluoride and various hormones in all preparations studied, including rat liver, heart, brain, epididymal adipose tissue, small intestine, renal cortex and renal medulla. The present results indicate that both prostaglandin antagonists may, in higher concentrations, act as nonspecific inhibitors of the catalytic unit of adenylate cyclase rather than specific antagonists of the prostaglandin effects on adenylate cyclase.

Adenylyl Cyclases↗

The effect of polyphloretin phosphate (PPP) on oral infiltration anaesthesia. An experimental investigation.

The possibilities to discontinue the anaesthetic effect using supplementary substances were studied. This investigation showed that administration of polyphloretin phosphate (PPP), 15 minutes after local anaesthetic injection, decreased the duration of infiltration anaesthesia of human teeth. The same result was also found when PPP was replaced by saline solution. However no effect on the duration of soft tissue anaesthesia was noted. There were no signs of adverse reactions.

Adult↗

The cutaneous reactions to kallikrein, prostaglandin and thurfyl nicotinate in chronic urticaria and the effect of polyphloretin phosphate.

The erythema and wealing resulting from the application of thurfyl nicotinate ointment (Trafuril) and from the inoculation of kallikrein has been studied in patients with chronic urticaria and normal controls. Polyphloretin phosphate (PPP) suppressed the reaction in controls but in patients with urticaria it increased the reactions to Trafuril and had little effect on the kallikrein reaction. PPP also suppressed the PGE2-induced erythma in normal controls but not in urticaria patients. In a separate study using fibrinolysis autography, prostaglandin (PG) E2 and PGF2alpha depressed fibrinolysis in the skin of two pigs and both kallikrein and Trafuril suppressed fibrinolysis in human skin. It is suggested that the inflammatory reaction induced by thurfyl nicotinate and kallikrein is mediated in part by a prostaglandin-like action. Several anomalies in the action of Trafuril in skin diseases can be explained if such prostaglandin-like activity is mediated in part through inhibition of fibrinolysis.

Chronic Disease↗

Polyphloretin phosphate reduces the algesic action of bradykinin by interfering with E-type prostaglandins.

(1) The method of the isolated perfused rabbit ear connected to the body by its nerve only was used to investigate the influence of the prostaglandin-antagonist polyphloretin phosphate (PPP) on the algesic effect of bradykinin (B) and acetylcholine (ACh). (2) Intra-arterial injections of B and ACh into the ear elicit a reflex fall in systemic blood pressure of the anaesthetized animal. PPP reduces this effects of B in proportion to the dose. The effect of ACh is reduced only to a small extent and only under higher concentrations of PPP than those necessary for inhibiting the effect of B. (3) Prostaglandin E1 (PGE1), when infused i.a. into the ear, enhances the effect of B and ACh by a sensitizing action on the perivascular pain receptors. PPP reduces or totally abolishes the PGE1-induced enhancement of the effect of B and ACh. (4) It is concluded that PPP reduces the effect of B mainly by inhibiting directly the pain enhancing action of the endogenously released PGs of the E-type. The effect of ACh is reduced only in the high concentration of PPP to a small extent probably by inhibiting the ACh-action rather than the sensitizing action of the only minimal released amounts of PGs. The PG-antagonizing action of PPP is further proven by the fact that during an additional infusion of PGE1 the enhanced effects of both B as well as ACh are reduced or abolished by PPP.

Acetylcholine↗

Effect of polyphloretin phosphate on the contraceptive action of a polyethylene intrauterine device in rats.

A polyethylene intrauterine device (IUD) inserted in one horn of the rat uterus on Day 2 of pregnancy prevented implantation in 9 out of 12 rats in the horn with the device. When polyphloretin phosphate (PPP), a substance known to inhibit alkaline phosphatase, was administered to such rats from Day 1 till Day 5 of pregnancy, the device prevented implantation in only 3 out of 12 rats in the horn with the device. PPP also significantly reduced the raised levels of endometrial alkaline phosphatase observed in the presence of the device. A significant rise in endometrial alkaline phosphatase was seen in such animals not administered PPP. It is suggested that there is a correlation between the anti-implantation effect of an IUD and raised levels of endometrial alkaline phosphatase in rats.

Alkaline Phosphatase↗

Effect of prostaglandin E1 and polyphloretin phosphate on hemolysis of human erythrocytes.

Prostaglandin E1 was found to reduce the hemolysis rate induced by various factors, such as frequent shakings, treatment with hog pancreatic phospholipase A2, the addition of active oxygens generated by a xanthine oxidase system, and the addition of a prostaglandin antagonist, polyphloretin phosphate (PPP). Prostaglandin E1 was found to act on the erythrocytes in such a way as to cause the phospholipids in the membrane to become more compactly arranged thus becoming less susceptible to the attack of hemolytic reagents. It was observed that the extents of hemolysis were different between erythrocytes from males and females and furthermore, it was shown that prostaglandin E1 clearly reduced the rate of hemolysis of erythrocytes from males, while, in females, the effects of prostaglandin E1 were less than those in erythrocytes from males.

Adult↗

The effect of polyphloretin phosphate on the aqueous flare response to alpha-melanocyte stimulating hormone.

The breakdown of the blood aqueous barrier caused by topical prostaglandin E1 (PGE1), prostaglandin E2 (PGE2) or subcutaneous alpha-melanocyte stimulating hormone (alpha-MSH) was quantified by measurements of the aqueous flare seen in the anterior chamber. Polyphloretin phosphate (PPP) administration subcutaneously was found to effectively block the protein leakage caused by all three traumatic stimuli. The same dose of PPP given intravenously inhibited effectively the flare response to PGE1 and alpha-MSH, whereas the effect of PGE2 was only slightly decreased. Significant inhibition by subconjunctival PPP was not achieved for any of the three stimuli. Assuming that PPP is a specific PG-antagonist the present results support the eariler suggestion that PGs take part in the barrier damaging action of alpha-MSH. However, it cannot be excluded that PPP acts on a step subsequent to PG. This step might be common to PGs- and alpha-MSH-effects on the barrier, explaining why PPP inhibits both types of trauma.

Administration, Topical↗

Antagonism of some smooth muscle actions of prostaglandins by polyphloretin phosphate.

1. The antagonism of the smooth muscle stimulating actions of PGF(2a) and PGE(2) by polyphloretin phosphate (PPP) was studied on several isolated smooth muscle preparations and on the blood pressure of the anaesthetized rabbit.2. PPP (2.5-20 mug/ml) reversibly inhibited contractions of the jird colon produced by PGE(2) or PGF(2a); PGF(2a) was more readily antagonized than PGE(2).3. PPP (2.5-30 mug/ml) reversibly antagonized contractions produced by PGE(2) and PGF(2a) on the isolated rabbit jejunum and uterus. In these preparations PPP antagonized PGE(2) as readily as PGF(2a).4. It is concluded that PPP is a selective antagonist to the prostaglandins on these tissues, for contractions produced by other agonists, such as acetylcholine, angiotensin, 5-hydroxytryptamine and bradykinin were not reduced by concentrations of PPP which markedly antagonized responses to the prostaglandins.5. Intravenous injections of PPP (25-200 mg/kg) resulted in a variable antagonism to the fall in blood pressure produced by intravenous injections of PGF(2a) in the anaesthetized rabbit; vasodepressor responses produced by PGE(2) and acetylcholine were not antagonized.6. The mechanism of this antagonism by PPP is not clear and must await further investigation.

Acetylcholine↗

Effects of prostaglandins E1, E2 and F2 alpha and polyphloretin phosphate of domestic fowl.

The predominant effect of PGE1, E2, and F2 alpha on systemic arterial pressure of domestic fowl is hypotension. PGE1 and E2 are approximately equiactive and PGF2 alpha is about 10 times less active than E1 and E2, PGE1 and E2 produce sudden hypotension with gradual recovery while F2 alpha produces fall in blood pressure with both slow onset and recovery. Polyphloretin phosphate itself produces depressor responses in chickens and antagonizes the depressor responses to the prostaglandins dose-dependently.

Acetylcholine↗